Aliya May, PA
Physician Assistant · Oldsmar, FLNPI 1902466402
Payments from drug & device makers
Across 328 payments — averaging $24.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$2K
- AbbVie$1K
- Axsome Therapeutics, Inc.$1K
- Neurocrine Biosciences, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$863
- Alkermes, Inc.$593
- plus $1K from 12 others
What the payments were for
- Food & beverage$7,84398%
- Education$1452%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 88 | $1,571 |
| AbbVie | 59 | $1,370 |
| Axsome Therapeutics, Inc. | 41 | $1,210 |
| Neurocrine Biosciences, Inc. | 32 | $1,099 |
| Otsuka America Pharmaceutical, Inc. | 37 | $863 |
| Alkermes, Inc. | 26 | $593 |
| Vanda Pharmaceuticals Inc. | 9 | $287 |
| E.r. Squibb & Sons, L.L.C. | 8 | $262 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $214 |
| Lundbeck LLC | 11 | $199 |
| Idorsia Pharmaceuticals US Inc | 3 | $170 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $33 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Sunovion Pharmaceuticals Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Novo Nordisk | 1 | $17 |
| Eisai Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$643
- LYBALVI$494
- VRAYLAR$335
- Auvelity$230
- Austedo XR$160
- CAPLYTA$125
- COBENFY$124
- ABILIFY ASIMTUFII$124
- ABILIFY MAINTENA$124
- QUVIVIQ$122
- REXULTI$119
- Fanapt$107
- UZEDY$106
How this compares
$7,987 in reported general payments places this provider in the 95th percentile of 8,062 physician assistant providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 93 | $765,231 |
| Austedo XrDeutetrabenazine | 77 | $554,171 |
| RexultiBrexpiprazole | 116 | $169,698 |
| AuvelityDextromethorphan Hbr/Bupropion | 110 | $102,425 |
| VraylarCariprazine Hcl | 63 | $95,035 |
| AristadaAripiprazole Lauroxil | 39 | $73,929 |
| UzedyRisperidone | 23 | $57,123 |
| Abilify MaintenaAripiprazole | 22 | $49,342 |
| LybalviOlanzapine/Samidorphan Malate | 28 | $47,870 |
| Invega SustennaPaliperidone Palmitate | 11 | $38,969 |
| CaplytaLumateperone Tosylate | 16 | $29,295 |
| Aripiprazole | 219 | $8,383 |
| TrintellixVortioxetine Hydrobromide | 13 | $8,331 |
| Quetiapine Fumarate | 333 | $5,954 |
| Divalproex Sodium | 139 | $4,078 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,099 | $765,23193 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Uzedy | $1,571 | $611,294100 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $863 | $219,040138 claims |
| Alkermes, Inc.Aristada, Lybalvi | $593 | $121,79967 claims |
| Axsome Therapeutics, Inc.Auvelity | $1,210 | $102,425110 claims |
| AbbVieVraylar | $1,370 | $95,03563 claims |
| Johnson & JohnsonInvega Sustenna | $15 | $38,96911 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $214 | $29,29516 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $22 | $8,33113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,062 physician assistant providers in Florida.
Other physician assistant in Oldsmar
- Richard MarshallPort Orange$988K
- Audrey BeckerSt Augustine$689K
- Kevin WilliamsTampa$647K
- Brian BonomoLecanto$559K
- Melissa SingletonOcala$482K
- Reeli ReinuMaitland$427K
- Jeanelle KingMiami$424K
- Risha BellomoOrlando$397K
- Jason BergerClearwater$344K
- Ashley MillerGainesville$328K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.